Latest Distribution Agreements News

AMP Limited reported a robust FY25 with underlying NPAT up 20.8%, driven by strong cashflow growth, cost reductions, and new product launches including AMP Bank GO and AMP Lifetime Pension. The company sets a steady course for FY26 with continued focus on retirement solutions and AI-driven innovation.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

Terragen Holdings has raised A$7 million through a strategic equity raising to fund scientific research and accelerate global commercialisation, while appointing Dr Michele Allan AO as its new Chair.

First Graphene has secured a strategic distribution and collaboration agreement with Syron GreenThrust Dynamics to supply its PureGRAPH products across India, SAARC nations, and the UAE, unlocking new industrial markets and potential local manufacturing.

4DMedical has rapidly commercialised its CT – VQ™ lung imaging technology following FDA clearance, securing major partnerships and regulatory approvals that position it for significant growth in North America.

Lumos Diagnostics reported a strong surge in FebriDx® sales alongside positive FDA feedback, securing full Medicare reimbursement and advancing key clinical studies.

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.

BetMakers Technology Group reported a robust Q2 FY26 with positive adjusted EBITDA and significant contract wins poised to fuel growth in the second half of the year.

BetMakers Technology Group reports a robust Q2 FY26 with 14.1% revenue growth and a $2.7 million positive Adjusted EBITDA, underpinned by key partnerships and margin expansion.

Control Bionics has secured a two-year US distribution agreement with AAC leader PRC-Saltillo to broaden access to its NeuroNode technology, enhancing communication options for users with complex needs.

icetana Limited reported steady growth in Q2 FY26 with a 36% increase in annual recurring revenue and expanded partnerships across APAC and the Middle East. The company’s cash flow improved, while product enhancements aim to strengthen its AI security offerings.

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.